טוען...
Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study
Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertaint...
שמור ב:
| הוצא לאור ב: | Clin Auton Res |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4763681/ https://ncbi.nlm.nih.gov/pubmed/25763826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10286-015-0281-2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|